SCHEMBL6823876

SCHEMBL6823876

O=C(NC1CCN(CCCCOc2cccc3c2C(=O)C(=C(C2CC2)C2CC2)O3)CC1)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 5/20 0.46
HTR1A P08908 2/20 0.46
DRD2 P14416 3/20 0.43
HTR2A P28223 2/20 0.43
DRD3 P35462 2/20 0.43
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
MCHR1 Q99705 1/20 0.41
DRD4 P21917 4/20 0.40
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823760 0.92 HTR7 (0.45) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL6820545 0.91 HTR7 (0.50) HTR7HTR1ADRD2HTR2ADRD4
SCHEMBL6826272 0.87 HTR7 (0.47) HTR7HTR1ADRD2HTR2ADRD4
SCHEMBL6820568 0.84 HTR7 (0.55) HTR7HTR1ADRD2HTR2AMCHR1
SCHEMBL6823392 0.84 HTR7 (0.49) HTR7HTR1ADRD2HTR2ADRD4
SCHEMBL6823762 0.83 HTR2A (0.45) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL6458101 0.83 HTR7 (0.54) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL6462598 0.83 HTR7 (0.54) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL6381981 0.83 HTR7 (0.49) HTR7HTR1ADRD2HTR2ADRD4
SCHEMBL6466592 0.82 HTR7 (0.55) HTR7HTR1ADRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004076444-A2 NOVEL HYDROXYCOUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC F. HOFFMANN-LA ROCHE AG (CH) 2004-09-10 WO claimed
WO-2004076444-A2 NOVEL HYDROXYCOUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC F. HOFFMANN-LA ROCHE AG (CH) 2004-09-10 WO disclosed